The 2026 FDA compounding ban, explained

The FDA’s April 30 proposal

With semaglutide and tirzepatide shortages officially resolved (May 2026), the FDA issued a "no clinical need" finding and proposed removing all three GLP-1-class molecules from the 503B bulks list. 503B outsourcing facilities, which supply most high-volume compounded GLP-1 sold through telehealth, would lose the ability to compound these drugs at scale, even if a future shortage occurs. The comment period runs through June 29, 2026.

Your transition options

1. 1. Branded manufacturer direct. NovoCare Direct (Wegovy $499/mo) or LillyDirect (Zepbound vials $349-499/mo) are the most durable routes. See our pricing comparison.
2. 2. 503A patient-specific compounding. May continue for documented medical necessity (allergy to an excipient, non-standard dosing). Not population-scale, but a path for specific clinical needs.
3. 3. Talk to your prescriber now. Do not wait for a final rule. A transition plan agreed in advance prevents a gap in therapy.

Frequently asked

Is compounded semaglutide being banned in 2026?

The FDA proposed (April 30, 2026) to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing "no clinical need" now that shortages have resolved. If finalized, 503B outsourcing facilities, the source of most high-volume compounded GLP-1, would be permanently barred from compounding these drugs, even during future shortages. The public comment period closes June 29, 2026. This is a proposal, not yet final.

What is the difference between 503A and 503B for this ban?

503B outsourcing facilities make compounded drugs in large batches under FDA registration and cGMP. 503A pharmacies make patient-specific prescriptions in smaller volumes under state board oversight. The proposed ban targets the 503B bulks list. 503A patient-specific compounding for documented medical necessity (allergy, alternative dosing) may continue under separate rules, but population-scale supply is what is at risk.

What happens to my prescription if I am on compounded GLP-1?

Nothing immediately, the proposal is not final and there is no instant cutoff. But if finalized, your telehealth provider may transition you to branded medication (NovoCare $499/mo, LillyDirect $349-499/mo) or to 503A patient-specific compounding if medically justified. Talk to your prescriber about a transition plan before any final rule takes effect.

Can I submit a comment to the FDA?

Yes. The public comment period is open until June 29, 2026 on Regulations.gov. Patients, prescribers, and pharmacies can submit. After June 29, the FDA reviews comments before issuing a final rule.